Treatment of Ren2 with the angiotensin‐type 1 receptor (AT1R) blocker, valsartan has been shown to reduce albuminuria, high blood pressure and increase renal ACE2 and NEP mRNAs expression (Whaley‐Connell et al., 2006). Here, MME is linked to hypertensive disorder.